Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: Induction of potent and long-lasting T-cell responses against cancer antigens

Cancer Research

Volumn 62, Issue 5, 2002, Pages 1477-1480

  Mattner, Frank ^a   Fleitmann, Julia Kristina ^a   Lingnau, Karen ^a   Schmidt, Walter ^a   Egyed, Alena ^a   Fritz, Jörg ^a   Zauner, Wolfgang ^a   Wittmann, Barbara ^a   Gorny, Irmina ^a   Berger, Manfred ^a   Kirlappos, Helen ^a   Otava, Aleksandr ^a   Birnstiel, Max L ^a   Buschle, Michael ^a  

^a INTERCELL AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

POLYARGININE; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; FEMALE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MOVEMENT; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PEPTIDES; T-LYMPHOCYTES; VACCINATION;

EID: 0036494274     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Living up to the legacy
2. Progress in human tumour immunology and immunotherapy
3. Vaccines and vaccination
4. The dendritic cell system and its role in immunogenicity
5. Dendritic cells as vectors for therapy
6. Cell-free tumor antigen peptide-based cancer vaccines
7. Tumor antigens recognized by T lymphocytes
8. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes
9. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay
10. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody
11. Dendritic cells of the skin
12. Dendritic cells and the control of immunity
13. Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells
14. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
15. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
16. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MCIR, and TRP-2 in vaccine-treated melanoma patients
17. In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: Intra-pinna immunization followed by restimulation in the peritoneal cavity
18. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties
19. Transloading of tumor antigen-derived peptides into antigen presenting cells
20. Extracellular antigen processing and presentation by immature dendritic cells
21. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
22. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection
23. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
24. Phenotypic analysis of antigen-specific T lymphocytes
25. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization
26. Human tumor antigens recognized by T lymphocytes
27. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
28. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
29. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers